Publications by authors named "Christina Billias"
Article Synopsis
- Trilaciclib has been shown to significantly reduce severe neutropenia rates in extensive-stage small cell lung cancer patients compared to a placebo plus chemotherapy regimen.
- A study at a single center found that patients receiving trilaciclib with chemotherapy experienced lower rates of severe neutropenia (3%) compared to those receiving chemotherapy alone (18%).
- The combination of trilaciclib and chemotherapy also led to fewer cases of severe anemia and thrombocytopenia, suggesting improved safety without negatively impacting survival outcomes for patients.
Objective: To determine the incidence of skeletal-related events among multiple myeloma patients who received chemotherapy without a bone-modifying agent (zoledronic acid and denosumab) versus those who received chemotherapy with a bone-modifying agent. The secondary objective was to determine the incidence of skeletal-related events in patients without any prior history of skeletal-related events and who were treated with zoledronic acid every four weeks versus those who received zoledronic acid at an extended interval of every twelve weeks. Additional secondary objectives included the incidence of nephrotoxicity, hypocalcemia and osteonecrosis of the jaw in all patients.
View Article and Find Full Text PDF